"Shengbai Oral Liquid" has been granted PCT international patent authorization

2023-11-08

Recently, the PCT international patent for Shengbai Oral Liquid (also known as "Drug For Treating Leukopenia, Preparation Method Thereof And use Thereof") applied for by Hubei Mengyang Pharmaceutical Co., Ltd. has been approved and authorized by the US Patent Office. At present, authorization has been obtained in Hong Kong, Macau, Australia, and the United States, marking the gradual integration of the company's intellectual property patents with international standards, greatly enhancing the protection of the company's core products and market competitiveness.

The Patent Cooperation Treaty (PCT) is an important international cooperation treaty in the field of patents. The company has obtained multiple international patent authorizations this time, which is a new breakthrough in intellectual property rights and lays a solid foundation for the internationalization of Shengbai oral liquid products in the future. Mengyang Pharmaceutical is committed to research in the field of tumor treatment related diseases, striving to inherit the essence of traditional Chinese medicine and promote the culture of traditional Chinese medicine. In the future, we will continue to deepen our efforts in the field of tumor related diseases, explore the treasure trove of traditional Chinese medicine, and contribute to the promotion of traditional Chinese medicine.




Hot news

Service hotline

0724-8886111

Address:3 Fuyao Yi Lu, Doudao District, Jingmen City, Hubei Province, China
Transmissionh:0724-8686500
Email:hbmy_monyan@163.com

COPYRIGHT© 2022 Hubei Mengyang Pharmaceutical Co., LTD. All Rights Reserved E ICP 11014915; Internet Drug Information Service Certificate No. : (E) - Non-business -2016-0032

Technical Support: SUMA